Zobrazeno 1 - 10
of 296
pro vyhledávání: '"Hiroshi Kagamu"'
Autor:
Shigehiro Yagishita, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Hidetoshi Hayashi, MD, PhD, Satoru Miura, MD, PhD, Koji Tamada, MD, PhD, Hiroshi Kagamu, MD, PhD, Akinobu Hamada, PhD, Mayu Ohuchi, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Satoshi Hara, MD, Takashi Kijima, MD, PhD, Fujita Masaki, MD, PhD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Masahiro Tatsuno, MSc, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100683- (2024)
Introduction: This study validated real-world pharmacokinetic (PK) data using an established population PK (PopPK) model for atezolizumab in Japanese patients with NSCLC and explored the relationship between PK parameters, effectiveness, and adverse
Externí odkaz:
https://doaj.org/article/5313a5b432ab4c3892187d0d69ddf659
Autor:
Ou Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, Hisao Imai, Ichiro Naruse, Hiroyuki Yamaguchi, Miki Itai, Kohei Taguchi, Megumi Uchida, Noriaki Sunaga, Toshitaka Maeno, Koichi Minato, Hiromi Tomono, Daiki Ogawara, Hiroshi Mukae, Yu Miura, Ayako Shiono, Atsuto Mouri, Hiroshi Kagamu, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. The prognostic usefulness of ctDNA after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are limited. Therefore, the pr
Externí odkaz:
https://doaj.org/article/136751bf535d4857a7d70d282fd7c6bf
Autor:
Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Kunihiko Kobayashi, Tomonori Kawasaki, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 29, Pp 2950-2961 (2023)
Abstract Background Vascular endothelial growth factor (VEGF) has been identified as one of the resistant mechanisms to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, the relationship between the efficacy of osi
Externí odkaz:
https://doaj.org/article/fece6ef98b054e98ae461b7a3a7353f3
Autor:
Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Takayuki Kishikawa, Ken Masubuchi, Takashi Osaki, Yosuke Miura, Yukihiro Umeda, Akihiro Ono, Hiroyuki Minemura, Yutaka Yamada, Junichi Nakagawa, Yuki Kozu, Hirokazu Taniguchi, Hiromitsu Ohta, Takashi Kasai, Kyoichi Kaira, Hiroshi Kagamu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2567-2578 (2023)
Abstract Background Factors predicting the response to pembrolizumab plus platinum and pemetrexed combination therapy (Pemb‐Plt‐PEM) in nonsquamous non‐small cell lung cancer (non‐sq NSCLC) are unclear. We investigated the Glasgow Prognostic
Externí odkaz:
https://doaj.org/article/94316acf290f494398a776598e298791
Autor:
Atsuto Mouri, Satoshi Watanabe, Takaaki Tokito, Yoshiaki Nagai, Yu Saida, Hisao Imai, Ou Yamaguchi, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu
Publikováno v:
Cancers, Vol 16, Iss 7, p 1409 (2024)
Nivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation followi
Externí odkaz:
https://doaj.org/article/a1dd98b83cd04202929d5213660b4788
Autor:
Kyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Shin Yanagisawa, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka, Tamotsu Ishizuka, Koichi Minato, Satoshi Suda, Hiroshi Kagamu, Keita Mori, Nobuhiko Seki, Ichiei Kuji
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Purpose To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monotherapy in patients with
Externí odkaz:
https://doaj.org/article/561845a46d094745b5ca09fd534e42c6
Autor:
Toru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi, Naoki Niikura
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background Elucidating the unique immunoregulatory mechanisms in breast cancer microenvironment may help develop new therapeutic strategies. Some studies have suggested that hormone receptors also have immune regulatory functions, but their
Externí odkaz:
https://doaj.org/article/2158c181c20343c3840692b855e95a9a
Autor:
Kyoichi Kaira, Ou Yamaguchi, Tomonori Kawasaki, Kousuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Kobayashi, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Aim Tumor-infiltrating lymphocytes (TILs) in the tumor and stroma are expected to accurately predict the efficacy of programmed death-1 (PD-1) blockade therapy. However, little is known about the prognostic significance of TILs in first-line
Externí odkaz:
https://doaj.org/article/51df83129f1f4f2b811f207816e4829f
Autor:
Ayako Shiono, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Hiroyuki Minemura, Yutaka Yamada, Takayuki Kishikawa, Yukihiro Umeda, Hiroki Takechi, Ou Yamaguchi, Atsuto Mouri, Kyoichi Kaira, Hirokazu Taniguchi, Koichi Minato, Hiroshi Kagamu
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 73-83 (2023)
Abstract Purpose The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive‐disease (ED) small‐cell lung cancer (SCLC). Methods
Externí odkaz:
https://doaj.org/article/7b714a5a6ae74295a24b9195992b391e
Autor:
Kiyomi Kuba, Hitoshi Inoue, Satoko Matsumura, Yuichiro Enoki, Yasunao Kogashiwa, Yasuhiro Ebihara, Mitsuhiko Nakahira, Tomoko Yamazaki, Masanari Yasuda, Kyoichi Kaira, Hiroshi Kagamu, Masashi Sugasawa
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Nivolumab, an immune checkpoint inhibitor is the first-line therapy for platinum-resistant recurrent/metastatic head and neck cancer, and highly effective for some patients. However, no factors have been identified that could predict respons
Externí odkaz:
https://doaj.org/article/909df39e74084006a23d036102c74d3a